

## Ad hoc Release

**Ad-hoc Release pursuant to Section 15 of the German Securities Trading Act  
(Wertpapierhandelsgesetz)**

### **Biofrontera AG: Distribution Agreement with Desitin for Ameluz<sup>®</sup> in Scandinavia**

Leverkusen, 6 February 2012 – Biofrontera Pharma GmbH, a fully-owned subsidiary of Biofrontera AG, has today signed an agreement with Desitin Arzneimittel GmbH, Hamburg, for the marketing and distribution of Ameluz<sup>®</sup> in Denmark, Sweden and Norway, with a preferred right of negotiation for Finland. Biofrontera receives a significant immediate down-payment and 35% of all of Desitin's net revenues with Ameluz<sup>®</sup>. Further details are made available in a parallel press release.

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen  
ISIN: DE0006046113  
WKN: 604611

Contact:  
Werner Pehlemann  
Biofrontera AG  
Tel.: +49 (0214) 87 63 20, Fax.: +49 (0214) 87 63 290  
E-mail: [w.pehlemann@biofrontera.com](mailto:w.pehlemann@biofrontera.com)